Connect with us

Featured

Goff Corp (OTCMKTS: GOFF) Trifecta & The Perfect Reverse Merger Runner (Forward Split, NFT Name Change & Discharge of Custodianship)

Published

1 year ago

on

Goff Corp (OTCMKTS: GOFF) is among the most exciting stocks in penny stocks that is on a bull run that has been going on for a while. Part of the trifecta, GOFF was a David Lazar SPAC before RM stock whizz George Sharp was awarded Custodianship. Since than Mr. Sharp has been awarded CEO and the majority voting block of stock recently winning two judgements against Mr. Warwick Calasse who has lost all claim to his shares. On the block now are another 78 million shares which would bring the total OS to just 99 million shares. GOFF has an ambitious vision to become the first publicly traded NFT Company. Recently GOFF announced it is entering the $40 billion NFT space and changing its name to Worldwide NFT as well as affecting a 3 for 1 forward stock split. The documents were submitted to FINRA in March and the name change is imminent. 

Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars. Two recent RM runners that stand out are TSNP which went from sub pennies (where we first wrote about it) to several dollars per share. The other is HRBR which went from a few cents (where we first wrote about it) to $3 plus. GOFF is part of Geroge Sharp’s trifecta, the stock is the perfect merger candidate, debt free except Mr. Sharps Judgment against the Company, very tight share structure, probably the most successful RM stock whizz in recent penny stocks history, known for doing it right, and legions of shareholders who are locked and loaded and many new investors buying in every day. Up next for GOFF is discharge of custodianship, forward split and name change, and the merger announcement. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Goff Corp (OTCMKTS: GOFF) currently operating out of New York, NY is a clean shell with 0 debt and a perfect merger candidate that was a David Lazar SPAC before George Sharp was awarded Custodianship.  The Company was incorporated in the State of Nevada on July 12, 2010 and operated as an exploration stage mining company, that engaged in exploration and mining of mineral properties. They focused on gold and silver production. Since 2013, the Company has been dormant 2021. Since custodianship was awarded to Mr. Sharp, all liabilities other than George Sharp’s judgement have been discharged by the Nevada District Court, Clark County. 

On May 26, 2021, George Sharp was appointed as custodian for the registrant, Goff Corp., by Order Granting Motion to (1) Intervene, (2) Remove Custodian, (3) Appoint George Sharp as Custodian, and (4) for Temporary Restraining Order and Preliminary Injunction on Order Shortening Time, Case No A-20-815182-B, Dept. No. XVI issued by the District Court of the State of Nevada in and for Clark County (the “Court Order”). Under his authority as Custodian George Sharp appointed himself as the sole member of the Board and President, Secretary and Treasurer of the Company by resolutions of the registrant’s Board of Directors on May 26, 2021. On August 29, 2021, in recognition of the $50,000 cash invested and $50,000 in consulting fees accrued by George Sharp for professional and regulatory fees to reinstate the registrant in the State of Nevada and to have the registrant become current in its filings under the SEC’s recently imposed requirements for public companies operating under SEC Rule 15c2-11, the Board issued 300,000 shares of the authorized “blank check” preferred stock to George Sharp with 10,000 votes for each share of preferred stock to give voting control to Mr. Sharp. The registrant is currently engaging an auditor and preparing the necessary filings with the SEC to have the registrant be subject to the reporting requirements of the SEC, including the filing of annual and quarterly financial reports. 

Since GOFF issued the 300,000 shares of Series A preferred stock to George Sharp it became aware through its transfer agent that in March 2013 the Company issued to a new President, Mr. Warwick Calasse, 5,000,000 shares of Series A preferred stock with each share of Series A preferred stock having the voting power of 294 shares of common stock. Since than George Sharp has won 2 judgements against Mr. Calasse who has lost all claim to his shares. 

In recent years there have been a number of hugely successful David Lazar custodianship/SPAC RM deals that have even spawned the message board; David Lazar, OTC SPAC’s/CUSTODIAN Plays on Investorshub.com.  Investor Sentiment in GOFF is high. 

https://twitter.com/asr2099/status/1523016195649064960

To Find out the inside Scoop on GOFF Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

GOFF

On September 8, 2021, Goff engaged BF Borgers CPA PC, a PCAOB licensed firm, as the registrant’s principal accountant to audit the registrant’s financial statements as of its fiscal years ended December 31, 2020 and December 31, 2019 for inclusion in a Form 10 to be filed prior to September 28, 2021 to meet the deadline established by the U.S. SEC under recent amendments to SEC Rule 15c2-11 requiring delinquent OTC market filers to provide current and publicly available information for broker-dealers to quote their securities in the OTC market. 

George Sharp is an experienced businessman with a diverse background in information technology and growth companies. After studying at Canada’s University of Waterloo, George joined the Engineering Department of the City of Calgary’s Electric System. There, George engineered a software application to more accurately examine the physical stresses on electrical wood poles. That effort garnered him recognition at the 1983 Stanford University Congress of Electrical Engineers. George was then recruited to join Northern Telecom in Bramalea, Ontario as a software engineering consultant. In the early 1990s, George founded Progressive Microsystem Designs to develop a series of business software applications for the emerging microcomputer market. The centerpiece of PMD was one of the first Human Resources Administration software products designed for microcomputers. Eventually, George relocated PMD to Southern California in order to better service the bulk of its clients. A former consultant to OTC Markets Group, George now provides services to publicly traded small companies seeking management advice; routes, including financing, towards progress; and, looking to stay onside of regulations. 

Microcapdaily was among the first to report on George Sharps TSNP on November 15, 2020 when the stock was trading around $0.003 just as it was beginning its historic rise to multi-dollars and the reverse merge into HMBL. We stated at the time: “TSNP is a clean shell operating out of Oklahoma City, Oklahoma. The Company recently announced it has entered into an agreement with HUMBL, LLC to merge the two entities. In an all-stock transaction, the members of HUMBL will receive preferred shares of Tesoro in exchange for their HUMBL holdings.”  

GOFF has an ambitious vision to become the first publicly traded NFT Company; according to a January 2021 report from Business Insider NFTs ballooned to a $41 billion market in 2021 and are catching up to the total size of the global fine art market. Currently there are around 28.6 million wallets trading NFTs as of December 2021. China is the country with the biggest interest in NFT opportunities. OpenSea as the largest peer-to-peer marketplace for NFTs, with a total trade volume of around $6.5 billion. The company has also helped to launch the rise of range of other competitors, like Axie Infinity, which trades around $2.1 billion at present.  

For more on GOFF Subscribe Right Now!

GOFF is easily among the most exciting situations on the OTC and speculators are heavily accumulating as the stock continues northbound. There are significant catalysts at play as the Company recently announced it is entering the $40 billion NFT space and changing its name to Worldwide NFT as well as affecting a 3 for 1 forward stock split. Part of the trifecta, GOFF was a David Lazar SPAC before RM stock whizz George Sharp was awarded Custodianship. Since than Mr. Sharp has been awarded CEO and the majority voting block of stock recently winning two judgements against Mr. Warwick Calasse who has lost all claim to his shares. On the block now are another 78 million shares which would bring the total OS to just 99 million shares. GOFF is part of Geroge Sharp’s trifecta (GVSI / SRNW) expected to fuel another summer of George, (TSNP & FORW were 2021 Summer of George) the stock is the perfect merger candidate, debt free, very tight share structure, probably the most successful RM stock whizz in recent penny stocks history, known for doing it right, and legions of shareholders who are locked and loaded and many new investors buying in every day. GOFF has an ambitious vision to become the first publicly traded NFT Company. Recently GOFF announced it is entering the $40 billion NFT space and changing its name to Worldwide NFT as well as affecting a 3 for 1 forward stock split. The documents were submitted to FINRA in March and the name change is imminent. Up next for GOFF is discharge of custodianship, forward split and name change, and the merger announcement into the NFT space. GOFF looks like its just getting started recently breaking through $0.50 resistance level GOFF has now made $0.50 its support level with an eye on $0.76 and blue skies ahead.  The stock has a fast-growing shareholder base including many big players in small caps, Youtubers, and internationally.  We first reported on GOFF when the stock was $0.16 We will be updating on GOFF when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GOFF.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GOFF either long or short and we have not been compensated for this article

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

12 hours ago

on

June 4, 2023

By

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by 3D Animation Production Company from Pixabay

Continue Reading

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

3 days ago

on

June 2, 2023

By

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

4 days ago

on

June 1, 2023

By

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.